SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
Abstract
:1. Introduction
2. Methods
2.1. The Study Design
2.2. Sampling Method
- Healthy people or those with well-controlled diseases.
- Adults over 18 years old.
- People who have received two doses of the Sinopharm vaccine at a 21-day interval.
- Exclusion criteria:
- People who have severe clinical conditions or are receiving immunosuppressive therapy.
- Less than 18 years old.
- People who received one dose of the Sinopharm vaccine.
- People who did not receive two doses of the Sinopharm vaccine at a 21-day interval.
- Pregnant women.
2.3. Data Collection
- Participants’ demographic data: age, gender, marital status, educational level, current place of residence (city or country), and job.
- Post-first dose symptoms and practices.
- Post-second dose symptoms and practices.
- Results of IgG anti-spike protein antibodies test and laboratory tests at day 18 after vaccination with Sinopharm vaccine. The survey was conducted from April to June 2021 in Egypt.
2.4. IgG Anti Spike Protein Antibody Test
3. Results
3.1. Demographic Data of the Participants
3.2. Symptoms and Practices Following the First Dose of the SINOPHARM Vaccine
3.3. Symptoms and Practices Following the Second Dose of the Sinopharm Vaccine
3.4. Results of IgG Anti Spike Protein Antibodies Test and Laboratory Tests at Day 18 after Vaccination with Sinopharm Vaccine
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sreepadmanabh, M.; Sahu, A.K.; Chande, A. COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. J. Biosci. 2020, 45, 148. [Google Scholar] [CrossRef] [PubMed]
- Callaway, E. Coronavirus Vaccines. Nature 2020, 580, 577. [Google Scholar] [CrossRef] [PubMed]
- Noda, K.; Matsuda, K.; Yagishita, S.; Maeda, K.; Akiyama, Y.; Terada-Hirashima, J.; Matsushita, H.; Iwata, S.; Yamashita, K.; Atarashi, Y.; et al. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci. Rep. 2021, 11, 5198. [Google Scholar] [CrossRef] [PubMed]
- Tarawneh, O.; Tarawneh, H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am. J. Hematol. 2021. [Google Scholar] [CrossRef] [PubMed]
- Patel, R.B.; Skaria, S.D.; Mansour, M.M.; Smaldone, G.C. Respiratory source control using a surgical mask: An in vitro study. J. Occup. Environ. Hyg. 2016, 13, 569–576. [Google Scholar] [CrossRef] [Green Version]
- Majeed, K.R.; Al-Fahad, D.; Jalood, H.H.; Hantosh, H.A.; Ali, M.K.; Sakthivel, S.; Williams, H.F.; Gibbins, J.M.; Patel, K.; Baksh, M.F.; et al. RhD blood type significantly influences susceptibility to contract COVID-19 among a study population in Iraq. F1000Research 2021, 10, 38. [Google Scholar] [CrossRef]
- Bwire, G.M. Coronavirus: Why men are more vulnerable to Covid-19 than women? SN Compr. Clin. Med. 2020, 2, 874–876. [Google Scholar] [CrossRef]
- Gralinski, L.E.; Bankhead, A.; Jeng, S.; Menachery, V.; Proll, S.; Belisle, S.E.; Matzke, M.; Webb-Robertson, B.-J.; Luna, M.L.; Shukla, A.K.; et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. MBio 2013, 4, e00271-13. [Google Scholar] [CrossRef] [Green Version]
- Yang, L.-L.; Yang, T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19). Chronic Dis. Transl. Med. 2020, 6, 79–86. [Google Scholar] [CrossRef]
- Solomon, Y.; Eshete, T.; Mekasha, B.; Assefa, W. COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine Among Health Professionals in Low-Income Country: Ethiopia. J. Multidiscip. Healthc. 2021, 14, 2577. [Google Scholar] [CrossRef]
- Elgendy, M.O.; Abdelrahman, M.A.; Osama, H.; El-Gendy, A.O.; Abdelrahim, M.E.A. Role of repeating quarantine instructions and healthy practices on COVID-19 patients and contacted persons to raise their awareness and adherence to quarantine instructions. Int. J. Clin. Pract. 2021, 75, e14694. [Google Scholar] [CrossRef] [PubMed]
- Stankevič, O.K. Commentary: The New Coronavirus COVID-19. Pac. J. Med. Sci. 2021, 21, 21–32. [Google Scholar]
- Menni, C.; Klaser, K.; May, A.; Polidori, L.; Capdevilia, J.; Louca, P.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Merino, J.; et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect. Dis. 2021, 21, 939–949. [Google Scholar] [CrossRef]
- El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.; Almukadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi, N.; et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int. J. Gen. Med. 2021, 14, 1389. [Google Scholar] [CrossRef] [PubMed]
- Dando, M.T.; Perry, C.M. Aprepitant. Drugs 2004, 64, 777–794. [Google Scholar] [CrossRef] [PubMed]
- Elgendy, O.M.; Abdelrahim, M.E. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. J. Med. Virol. 2021, 93, 6535–6543. [Google Scholar] [CrossRef]
- Aprepitant as a Combinant with Dexamethasone Reduces the Inflammation via Neurokinin 1 Receptor Antagonism in Severe to Critical COVID-19 Patients and Potentiates Respiratory Recovery: A Novel Therapeutic Approach. Available online: https://www.medrxiv.org/content/10.1101/2020.08.01.20166678v3 (accessed on 18 October 2021).
- Khadka, S.; Yuchi, A.; Shretha, D.B.; Budhathoki, P.; Al-Subari, S.M.M.; Alhouzani, T.M.Z.; Butt, I.A. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic. Altern. Health Med. 2020, 26, 100–107. [Google Scholar]
- Elgendy, M.O.; El-Gendy, A.O.; Abdelrahim, M.E. Public awareness in Egypt about COVID-19 spread in the early phase of the pandemic. Patient Educ. Couns. 2020, 103, 2598–2601. [Google Scholar] [CrossRef]
- Elgendy, M.O.; Elmawla, M.N.A.; Hamied, A.M.A.; El Gendy, S.O.; Abdelrahim, M.E.A. COVID-19 patients and contacted person awareness about home quarantine instructions. Int. J. Clin. Pract. 2021, 75, e13810. [Google Scholar] [CrossRef]
- Zawbaa, H.M.; Osama, H.; El-Gendy, A.; Saeed, H.; Harb, H.S.; Madney, Y.M.; Abdelrahman, M.; Mohsen, M.; Ali, A.M.A.; Nicola, M.; et al. Effect of mutation and vaccination on spread, severity, and mortality of COVID-19 disease. J. Med. Virol. 2021, 94, 197–204. [Google Scholar] [CrossRef]
- Hatmal, M.m.M.; Al-Hatamleh, M.; Olaimat, A.N.; Hatmal, M.; Alhaj-Qasem, D.M.; Olaimat, T.M.; Mohamud, R. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines 2021, 9, 556. [Google Scholar] [CrossRef] [PubMed]
- Sayed, A.M.; Khalaf, A.M.; Abdelrahim, M.E.A.; Elgendy, M.O. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. Int. J. Clin. Pract. 2021, 75, e13877. [Google Scholar] [CrossRef] [PubMed]
- Mehboob, R.; Lavezzi, A.M. Neuropathological explanation of minimal COVID-19 infection rate in newborns, infants and children—A mystery so far. New insight into the role of Substance P. J. Neurol. Sci. 2021, 420, 117276. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Wang, X.-J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genom. 2020, 47, 119–121. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Number (%) |
---|---|
Gender | |
Male | 18 (15%) |
Female | 102 (85%) |
Age in years | |
From 18 to 35 years | 57 (47.5%) |
From 35 to 45 years | 33 (27.5%) |
From 45 to 55 years | 9 (7.5%) |
More than 55 years | 21 (17.5%) |
Marital status | |
Unmarried | 31 (26%) |
Married | 89 (74%) |
Current residence place | |
City | 92 (77%) |
Country | 28 (23%) |
Job | |
No work | 30 (25%) |
I am a health care worker | 63 (55%) |
I work in another field | 24 (20%) |
Question | Number (%) |
---|---|
1—What are the symptoms that you felt after you received the first dose of Sinopharm vaccine? | |
• Pain, redness, or swelling where the vaccine was injected | 63 (52.5%) |
• Fever | 12 (10%) |
• Sore throat | 3 (2.5%) |
• Headache | 18 (15%) |
• Muscle pain | 12 (10%) |
• Excessive sweating | 0% |
• Joint pain | 9 (7.5%) |
• Feeling dizzy | 6 (5%) |
• Abdominal pain | 0% |
• Decreased appetite | 3 (2.5%) |
• Nausea and vomiting | 0% |
• Diarrhea | 0% |
• Cough | 3 (2.5%) |
• Allergies and rashes | 3 (2.5%) |
• Runny nose | 12 (10%) |
• Fatigue and lethargy | 60 (50%) |
• Convulsions | 0% |
• Swollen lymph nodes | 0% |
• Any blood clots | 0% |
• Inflammation of the nervous system, including numbness, tingling and loss of sensation | 3 (2.5%) |
• I didn’t feel any side effects | 30 (25%) |
2—To what extent do you rate the severity of these symptoms and complications? | |
• Mild | 59 (49%) |
• Moderate | 22 (18%) |
• Sever | 9 (8%) |
• I didn’t feel any side effects | 30 (25%) |
3—Symptoms appeared after the first dose during | |
• The first day after receiving the vaccine | 81 (67.5%) |
• The second day after receiving the vaccine | 3 (2.5%) |
• The third day after receiving the vaccine | 6 (5%) |
• After the third day from receiving the vaccine | 0% |
• I didn’t feel any side effects | 30 (25%) |
4—The symptoms that appeared after the first dose persisted for; | |
• One day | 27 (22.5%) |
• Two days | 36 (30%) |
• More than two days | 27 (22.5%) |
• I didn’t feel any side effects | 30 (25%) |
5—You have taken pain relievers. | |
• Before taking the first dose of the vaccine | 0% |
• After taking the first dose of the vaccine | 27 (22.5%) |
• I didn’t take any painkillers | 93 (77.5%) |
Question | Number (%) |
---|---|
1—I took the second dose of the vaccine after | |
• Two weeks after the first dose | 0% |
• Three weeks after the first dose | 108 (90%) |
• Four weeks after the first dose | 0% |
• More than four weeks after receiving the first dose | 12 (10%) |
2—Were you infected with the corona virus between the first and second doses (or you had severe symptoms of corona for more than two days after receiving the first dose) | |
• Yes | 12 (10%) |
• No | 108 (90%) |
3—What are the symptoms that you felt after you received the second dose of Sinopharm vaccine? | |
• Pain, redness, or swelling where the vaccine was injected | 15 (12.5%) |
• Fever | 3 (2.5%) |
• Sore throat | 6 (5%) |
• Headache | 12 (10%) |
• Muscle pain | 15 (12.5%) |
• Excessive sweating | 0% |
• Joint pain | 6 (5%) |
• Feeling dizzy | 3 (2.5%) |
• Abdominal pain | 0% |
• Decreased appetite | 0% |
• Nausea and vomiting | 0% |
• Diarrhea | 0% |
• Cough | 0% |
• Allergies and rashes | 6 (5%) |
• Runny nose | 9 (7.5%) |
• Fatigue and lethargy | 54 (45%) |
• Convulsions | 0% |
• Swollen lymph nodes | 0% |
• Any blood clots | 0% |
• Inflammation of the nervous system, including numbness, tingling, and loss of sensation | 0% |
• I didn’t feel any side effects | 45 (37.5%) |
4—To what extent do you rate the severity of these symptoms and complications? | |
• Mild | 39 (32.5%) |
• Moderate | 27 (22.5%) |
• Sever | 9 (7.5%) |
• I didn’t feel any side effects | 45 (37.5%) |
5—Symptoms appeared after the second dose during | |
• The first day after receiving the vaccine | 54 (45%) |
• The second day after receiving the vaccine | 15 (12.5%) |
• The third day after receiving the vaccine | 0% |
• After the third day from receiving the vaccine | 6 (5%) |
• I didn’t feel any side effects | 45 (37.5%) |
6—The symptoms that appeared after the second dose persisted for | |
• One day | 27 (22.5%) |
• Two days | 18 (15%) |
• More than two days | 30 (25%) |
• I didn’t feel any side effects | 45 (37.5%) |
7—You have taken pain relievers | |
• Before taking the second dose of the vaccine | 0% |
• After taking the second dose of the vaccine | 24 (20%) |
• I didn’t take any painkillers after taking the second dose of the vaccine. | 96 (80%) |
Question | Results |
---|---|
1—Have you had corona infection before? | |
• Yes | 16% |
• No | 84% |
2—Results of IgG anti spike protein antibodies test | |
• Positive (more than 1) | 49% |
• Negative (less than 1) | 51% |
3—Average of positive results of quantitative IgG anti spike protein antibodies test for the cases with a previous coronavirus infection during the four months before vaccination (for 16% of the participants) | 147 AU/mL |
4—Average of positive results of quantitative IgG anti spike protein antibodies test for the cases with no previous coronavirus infection before vaccination (for 33% of the participants) | 40 AU/mL |
5—Gender | |
Positive positive results of quantitative IgG anti spike protein antibodies test | |
• Male | 52% |
• Female | 48% |
Negative positive results of quantitative IgG anti spike protein antibodies test | |
• Male | 24% |
• Female | 76% |
Average of positive results of quantitative IgG anti spike protein antibodies test | |
• Male | 83 AU/mL |
• Female | 50 AU/mL |
6—Age in years | |
Positive positive results of quantitative IgG anti spike protein antibodies test | |
• From 18 to 40 years | 75% |
• From 41 to 60 years | 20.80% |
• More than 60 years | 4.20% |
Negative positive results of quantitative IgG anti spike protein antibodies test | |
• From 18 to 40 years | 45% |
• From 41 to 60 years | 33% |
• More than 60 years | 22% |
Average of positive results of quantitative IgG anti spike protein antibodies test | |
• From 18 to 40 years | 72 AU/mL |
• From 41 to 60 years | 56 AU/mL |
• More than 60 years | 29 AU/mL |
7—Average of laboratory parameters for the positive IgG anti spike protein antibodies cases | |
- Hemoglobin | 12.6 |
- Platelets | 263 |
- Leucocytes | 7.9 |
- Neutrophils | 53% |
- Lymphocytes | 42% |
- ESR | 21 |
- SGOT | 20 |
- SGPT | 20.5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Elgendy, M.O.; El-Gendy, A.O.; Alzarea, A.I.; Mahmoud, S.; Alqahtani, S.S.; Fahmy, A.M.; El-Seedi, H.R.; Sayed, A.M.; Alatawi, A.D.; Abdelrahim, M.E.A.; et al. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Vaccines 2022, 10, 18. https://doi.org/10.3390/vaccines10010018
Elgendy MO, El-Gendy AO, Alzarea AI, Mahmoud S, Alqahtani SS, Fahmy AM, El-Seedi HR, Sayed AM, Alatawi AD, Abdelrahim MEA, et al. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Vaccines. 2022; 10(1):18. https://doi.org/10.3390/vaccines10010018
Chicago/Turabian StyleElgendy, Marwa O., Ahmed O. El-Gendy, Abdulaziz Ibrahim Alzarea, Sarah Mahmoud, Saad S. Alqahtani, Alzhraa M. Fahmy, Hesham R. El-Seedi, Ahmed M. Sayed, Ahmed D. Alatawi, Mohamed E. A. Abdelrahim, and et al. 2022. "SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population" Vaccines 10, no. 1: 18. https://doi.org/10.3390/vaccines10010018
APA StyleElgendy, M. O., El-Gendy, A. O., Alzarea, A. I., Mahmoud, S., Alqahtani, S. S., Fahmy, A. M., El-Seedi, H. R., Sayed, A. M., Alatawi, A. D., Abdelrahim, M. E. A., & Alanazi, A. S. (2022). SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Vaccines, 10(1), 18. https://doi.org/10.3390/vaccines10010018